Results 21 to 30 of about 23,672 (222)

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice

BMC Endocrine Disorders, 2020
Background Acromegaly patients managed on Somatostatin receptor ligands (SRLs), the most common first-line pharmacotherapy for acromegaly, may still experience acromegaly symptoms such as headache, sweating, fatigue, soft tissue swelling, and joint pain,
Eliza B. Geer, Jill Sisco, Daphne T. Adelman, William H. Ludlam, Asi Haviv, Shuqian Liu, Susan D. Mathias, Dana Gelbaum, Lizheng Shi   +8 more
doaj   +1 more source

Acromegaly without acral anomalies [PDF]

Romanian Journal of Medical Practice, 2021
Early recognition of a pituitary secretor tumor offers a better prognostic; thus acromegaly might be recognized before the actual clinical picture of acromegaly is detectable.
Mara Carsote, Florica Sandru, Diana Elena Rentea, Claudia Mehedintu, Stefania Zugravu, Corina Chirita, Mihai Cristian Dumitrascu   +6 more
doaj   +1 more source

Static and Dynamic Balance Is Impaired in Patients With Long-Term, Well-Controlled Acromegaly: A Cross-Sectional Study. [PDF]

Clin Endocrinol (Oxf)
ABSTRACT Objective Balance impairment is an underrecognized complication of acromegaly with potentially serious consequences for affected patients. In this study, we aimed to assess the balance in patients with long‐term acromegaly compared to non‐acromegalic controls. Design Cross‐sectional study.
Rosendal C, Kvist AV, Hirata RP, Vestergaard P, Dal J.   +4 more
europepmc   +2 more sources

Acromegaly presenting with myelopathy due to ossification of posterior longitudinal ligament: a case report

BMC Musculoskeletal Disorders, 2021
Background Acromegaly is a rare disease caused by high serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), often originating from a pituitary adenoma.
Daisuke Kamakura, Katsunori Fukutake, Kazumasa Nakamura, Shintaro Tsuge, Keiji Hasegawa, Naobumi Tochigi, Akihito Wada, Tetsuo Mikami, Hiroshi Takahashi   +8 more
doaj   +1 more source

Rheumatic manifestations of acromegaly [PDF]

Остеопороз и остеопатии, 2020
Acromegaly is a chronic endocrine disease characterized by excessive secretion of growth hormone (GH), which, in turn, leads to increased insulin-like growth factor 1 (IGF-1) secretion by the liver.
Taras S. Panevin, Lyudmila I. Alekseeva, Galina A. Melnichenko   +2 more
doaj   +1 more source

Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Risk in Acromegaly Indicates Persistence of Cardiac Risks Despite Biochemical Disease Control. [PDF]

J Clin Med
Karadeniz Y, Karakose M.
europepmc   +3 more sources

Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients

Frontiers in Endocrinology, 2019
Introduction: The vitamin D receptor (VDR) gene is one of the most widely studied tumorigenesis-related genes. The primary objective of this study was assessment of possible roles of VDR gene polymorphisms in acromegaly, with regard to the activity of ...
Aleksandra Jawiarczyk-Przybyłowska, Jowita Halupczok-Żyła, Katarzyna Kolačkov, Łukasz Gojny, Agnieszka Zembska, Marek Bolanowski   +5 more
doaj   +1 more source

Heat Intolerance and Hyperhidrosis as the only Presenting Manifestations of Acromegaly: A Case Report [PDF]

Journal of Clinical and Diagnostic Research, 2020
Acromegaly is a state of Growth Hormone (GH) excess characterised by coarse facial features, acral enlargement, hyperhidrosis, headache, visual disturbances and visceromegaly. The most common cause of acromegaly is pituitary adenoma.
TN Kamalesh, HA VIJAYA SARATHY, NT SREEDEVI   +2 more
doaj   +1 more source

Extra-hepatic Acromegaly [PDF]

US Endocrinology, 2010
After the introduction of somatostatin analogs (LA-SMSA) and the growth hormone (GH) receptor antagonist, pegvisomant (Peg-v) normal serum insulin-like growth factor-1 (IGF-1) concentrations in virtually every patients with acromegaly is possible. The impact of these products on the GH–IGF1 axis is completely different.
Franck, Sanne E., van der Lely, Aart Jan, Neggers, Sebastian   +2 more
openaire   +3 more sources

Serum Levels of Asprosin, a Novel Adipokine, Are Significantly Lowered in Patients with Acromegaly

International Journal of Endocrinology, 2020
Background. Asprosin is a novel identified adipokine secreted mainly by white adipose tissue, which is elevated in metabolic diseases such as diabetes and obesity.
Xiaoan Ke, Lian Duan, Fengying Gong, Yuelun Zhang, Kan Deng, Yong Yao, Linjie Wang, Hui Pan, Huijuan Zhu   +8 more
doaj   +1 more source